Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) assess and monitor cognitive function and psychiatric symptoms in Veterans post-COVID; 2) evaluate biomarkers of inflammation and signaling pathways associated with viral infection and neuropsychiatric function; and 3) integrate neuropsychiatric and neurological findings with biological data to identify biomarkers and clinical endpoints associated with disease progression or severity, as well as those for promoting brain repair and attenuating those symptoms.

Who May Be Eligible (Plain English)

Who May Qualify: Eligible participants will: - have a history of SARS-CoV-2 infection 4 weeks prior to enrollment, defined as a positive PCR or home antigen test - be able to give willing to sign a consent form as determined by brief cognitive exam and evaluation of understanding of the risks, benefits, and voluntary nature of the study Additionally, participants enrolled as part of the neuro-PASC group must also: - currently experience neuro-PASC symptoms, not present prior to infection, as confirmed by the "Long COVID-19 Symptom Assessment" scale, a self-report measure that consists of 46 common COVID-19 sequela symptoms Who Should NOT Join This Trial: Exclusion criteria for all groups: - diagnosed with dementia, traumatic brain injury, a neurological syndrome (e.g. Parkinson disease, Alzheimer disease), or other progressive cognitive disorder before SARS-CoV-2 infection - diagnosed with a mood or psychotic disorder before SARS-CoV-2 infection - history of fibromyalgia or chronic fatigue syndrome prior to SARS-CoV-2 infection - unstable medical conditions or active uncontrolled autoimmune or inflammatory conditions Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: Eligible participants will: * have a history of SARS-CoV-2 infection 4 weeks prior to enrollment, defined as a positive PCR or home antigen test * be able to give informed consent as determined by brief cognitive exam and evaluation of understanding of the risks, benefits, and voluntary nature of the study Additionally, participants enrolled as part of the neuro-PASC group must also: * currently experience neuro-PASC symptoms, not present prior to infection, as confirmed by the "Long COVID-19 Symptom Assessment" scale, a self-report measure that consists of 46 common COVID-19 sequela symptoms Exclusion Criteria: Exclusion criteria for all groups: * diagnosed with dementia, traumatic brain injury, a neurological syndrome (e.g. Parkinson disease, Alzheimer disease), or other progressive cognitive disorder before SARS-CoV-2 infection * diagnosed with a mood or psychotic disorder before SARS-CoV-2 infection * history of fibromyalgia or chronic fatigue syndrome prior to SARS-CoV-2 infection * unstable medical conditions or active uncontrolled autoimmune or inflammatory conditions

Locations (2)

VA Portland Health Care System, Portland, OR
Portland, Oregon, United States
James H. Quillen VA Medical Center, Mountain Home, TN
Mountain Home, Tennessee, United States